#astrazeneca

#astrazeneca

RSV is a seasonal virus that lands tens of thousands of young children in the hospital every year.On Thursday, advisors to the FDA voted in favor of approving a long-acting antibody that protects infants from RSV. Christoph Soeder/Picture Alliance via Getty Images A panel of advisers to the Food and Drug Administration have recommended that the agency approve a new antibody drug to protect infants from serious lung illnesses caused by respiratory syncytial virus, also known as RSV.

A Food and Drug Administration advisory panel recommended approval of a monoclonal antibody shot aimed at preventing a potentially lethal pathogen, respiratory syncytial virus, or R.S.V., in infants and vulnerable toddlers.The treatment, called Beyfortus by its developers Sanofi and AstraZeneca, would be the second such therapy that the F.D.A. has allowed to be given to very young children to prevent R.S.V., which is a leading killer of infants and toddlers globally.

A new drug to prevent severe RSV infections could soon be available for young babies.Up to 80,000 young kids get hospitalized with RSV each year in the U.S. ARI SHAPIRO, HOST: Up to 80,000 young kids get hospitalized with RSV each year in the U.S, and it was especially bad this past season.But there's a new drug that could bring those numbers down significantly.

As a virus leaves some babies under the age of two wheezing  adding to the pressure on Canada's hospitals  drug makers are working on new treatment and vaccine options for the illness.Respiratory syncytial virus or RSV gets the "S" in its name for large cells known as syncytia that form when infected cells fuse.

A new vaccine that protects babies against a common and potentially dangerous winter virus has now been approved by the UK's regulator.The single jab Nirsevimab will help prevent babies getting severe chest infections like pneumonia, and lasts for around six months.Respiratory syncytial virus (RSV) spreads easily in coughs and sneezes, and almost all children have had it by the time they're two years-old.

Of the three respiratory viruses Americans are grappling with this winter, two  the coronavirus and the flu  are well-known threats.The third, respiratory syncytial virus, which already has sent thousands of children to hospitals, is a mystery to many.To pediatricians, however, R.S.V. is all too familiar.

A first-of-its-kind RSV vaccine for pregnant women guards their newborns against the scary respiratory virus - and federal health advisers on Thursday backed Pfizer's shot despite some lingering questions.RSV fills hospitals with wheezing babies each fall and winter, and the virus struck earlier than usual and especially hard in the U.S. this past year.

By Lauran Neergaard | Associated Press WASHINGTON A first-of-its-kind RSV vaccine for pregnant women guards their newborns against the scary respiratory virus - and federal health advisers on Thursday backed Pfizer's shot despite some lingering questions.RSV fills hospitals with wheezing babies each fall and winter, and the virus struck earlier than usual and especially hard in the U.S. this past year.

An advisory panel to the Food and Drug Administration voted on Thursday in favor of approving a vaccine by Pfizer to prevent the severe respiratory virus that is a potentially deadly threat to infants.The vaccine would be the first to protect babies from respiratory syncytial virus, or R.S.V., which is the reason many infants are admitted to children's hospitals each year and kills several hundred under 5 each year.

Young women who received at least one dose of the Covid vaccine made by AstraZeneca may have been more likely to die of a heart problem in the 12 weeks after their vaccination, according to an analysis of immunization and death records in Britain released on Monday.Those findings carry a big caveat: Britain withdrew AstraZeneca's vaccine use for young people under 30 in April 2021, citing the risk of rare but dangerous blood clots.

The US Food and Drug Administration on Thursday halted the emergency use authorization of Evusheld because it does not appear to protect against Covid-19 from viral variants currently circulating in the United States.Evusheld is a monoclonal antibody therapy used to prevent Covid-19 in immunocompromised people, who are less likely to generate an immune response from Covid-19 vaccination.

The US Food and Drug Administration has accepted a biologics license application for a long-acting antibody for the prevention of lower respiratory tract infections caused by the respiratory syncytial virus, according to the developers of the antibody.If approved, it could be available for use in some infants and toddlers later this year.

Qlik has closed its acquisition of Talend, tying together two data analytics and visualizion vendors backed by private equity biz Thoma Bravo.The resulting combined company will be led by CEO Mike Capone, formerly CEO of Qlik.Christal Bemont, former Talend CEO, left earlier this year during the take-over process as an interim management team took charge.

The Food and Drug Administration on Wednesday approved GSK's vaccine for the respiratory syncytial virus, or R.S.V., for adults who are 60 and older, the company said.The vaccine, to be sold as Arexvy, appears to be the first in the world approved for sale to protect older adults.Image An transmission electron microscopic image of R.S.V.Credit...Centers for Disease Control and Prevention The F.D.A. estimates that R.S.V. is associated with 6,000 to 10,000 deaths each year in adults 65 and older and at least 60,000 hospitalizations in that age group.

Jeremy Hunt has launched a flurry of tax breaks to encourage investment by businesses after the double blow of microchip designer Arm opting for a New York stock market listing and AstraZeneca deciding to build a new factory in Dublin.Businesses that invest in IT equipment and machinery will be able to claim back the cost by writing it off against tax on their profits, the chancellor announced in his budget on Wednesday.

After hours of deliberation over safety concerns, a Food and Drug Administration advisory panel on Wednesday recommended approval of a second vaccine for the respiratory syncytial virus in older adults, advancing the first shots against an illness that can be deadly for the very young and the very old.

This is an excerpt from Second Opinion, a weekly analysis of health and medical science news emailed to subscribers.If you haven't subscribed, you can do that by clicking here.Growing calls to reinstate mask mandates aren't being heeded by health officials.But what impact would mask mandates across Canada actually have on the surge of RSV and flu straining children's hospitals?

I'm still working at home, but only just.Before the pandemic, Melanie Green loved her job in a bustling police control room.But the drugs she takes for arthritis suppress her immune system and Green won't risk going back into the workplace while Covid continues to circulate.It's a busy environment with people coming in and out at all times of day.

Whether you get it from a vaccine or an infection, COVID-19 immunity does not last forever.In a study published May 3 in JAMA Network Open, researchers combed through studies to determine just how long protection from the shots endures.The scientists, led by a team from Italy, analyzed 40 studies that documented people's vaccination status and their subsequent infections with COVID-19, confirmed by lab tests.

For free real time breaking news alerts sent straight to your inbox sign up to our breaking news emails Sign up to our free breaking news emails The papers at the end of the working week are led by soaring energy bills and interest rates, as well as the earthquakes in the Middle East and the search for missing mother Nicola Bulley.

WASHINGTON The overdose-reversing drug naloxone should be made available over the counter to aid the national response to the opioid crisis, U.S. health advisers said Wednesday.The panel of Food and Drug Administration experts voted unanimously in favor of the switch after a full day of presentations and discussions centered on whether untrained users would be able to safely and effectively use the nasal spray in emergency situations.

The 87-acre field of weeds and rubble with a view of Treasure Island, downtown San Francisco, the Berkeley shoreline and the Bay Bridge was once Stauffer Chemical.Climate models show this acreage nearly surrounded by water in just a few decades.The company dumped iron pyrite cylinders into the marsh near the site and made pesticides, herbicides and fertilizers.

Concerns around the AstraZeneca Covid vaccine were overblown by the media, the company's chief executive has said.Sir Pascal Soriot was speaking after he was knighted by the King at Windsor Castle on Wednesday.Among those also honoured at the investiture ceremony was presenter Matt Baker, actor Damian Lewis, Coronation Street star William Roache, and film director Sir John Boorman.

Drugs giant AstraZeneca has abandoned plans to seek approval for its Covid-19 jab in the US as it revealed falling sales of the vaccine worldwide.The Anglo-Swedish group, which developed the Vaxzevria vaccine with Oxford University, revealed in its third-quarter results that it would drop an application with the Food and Drug Administration (FDA) in the US and instead focus its efforts elsewhere globally, including for its use as a booster.

The boss of Britain's biggest drugmaker has said that the UK and the rest of Europe are falling behind China and the US in the creation of biotech firms and clinical trials of new medicines.Pascal Soriot, chief executive of AstraZeneca, said that while China had seen an explosion of biotech companies and a rapid expansion of clinical trials, the UK and EU had posted declines.

Rishi Sunak's government will not lay out its response to rival US and EU green industrial strategies until the autumn, chancellor Jeremy Hunt has said.Business leaders are expecting a host of climate and energy policies on Thursday that would spur Britain's investment in green technology.But Mr Hunt said the government would not offer a full national response to major green investment initiatives made in the US and EU until the autumn.

Whenever Andrew Bailey, the governor of the Bank of England, talks about the economy, he is forced to mention the toll taken by Brexit.Business leaders, initially reluctant to criticise the Tory decision to quit the EU, have begun to find their voice.Most recently, leading City figure Guy Hands called Brexit a complete disaster and a bunch of total lies that has harmed large parts of the economy.

For free real time breaking news alerts sent straight to your inbox sign up to our breaking news emails Sign up to our free breaking news emails Rishi Sunak is facing rebellion from a coalition of Conservative MPs over April's planned rise in corporation tax.The leaders of several backbench Tory factions have written to the prime minister to urge him to abandon his plan to hike the tax from 19 to 25 per cent ahead of the March Budget.

Before we get on to Brexit don't worry: we shall I want to draw attention to what I regard as the epitome of the meanness and duplicity of what is indubitably the worst government of most of our lifetimes.Sorry, did I say government?A neighbour asked me the other day if I was aware of a new oxymoron.

Recent news about the UK economy has been a series of staggering highs and lows.The highs have often featured UK companies.Profits have reached record levels, as in turn have the indices that track the value of those companies' shares, providing a bonanza for executives and shareholders alike.The lows have featured British households.

London stocks fell after trading in Europe was knocked by rampant inflation across the continent.The FTSE 100 was also impacted by weaker shares from banking firms after the latest quarterly figures from NatWest disappointed.The top index finished the day down 26.02 points, or 0.37%, at 7,047.67.Michael Hewson, chief market analyst at CMC Markets UK, said: A rebound in yields, as well as the US dollar appears to be weighing on European markets today after the latest inflation numbers in Europe saw headline prices surge in October, with German CPI surging to 11.6%, and Italy CPI rising by 12.8%.